TG Therapeutics CEO to speak at Jefferies Global Healthcare Conference on June 3, 2026

TG Therapeutics announced that its CEO, Michael S. Weiss, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 3, 2026. The event will be webcast live on the company's website. TG Therapeutics is a biotechnology company focused on treatments for B-cell diseases and has FDA approval for BRIUMVI® to treat multiple sclerosis. This appearance highlights the company's ongoing engagement with investors and the healthcare community.